EKF Diagnostics Holdings PLC Exercise of Options and Total Voting Rights (6907A)
October 01 2020 - 1:00AM
UK Regulatory
TIDMEKF
RNS Number : 6907A
EKF Diagnostics Holdings PLC
01 October 2020
EKF Diagnostics Holdings plc
("EKF" or the "Company")
Exercise of Options and Total Voting Rights
Exercise of options
EKF Diagnostics Holdings plc (AIM: EKF), the AIM quoted
point-of-care business, announces that it has issued and allotted
400,000 new ordinary shares of one pence each in the share capital
of the Company ("Ordinary Shares") following an exercise of options
on 30 September 2020. The options had an exercise price of 27.25
pence per Ordinary Share.
Application will be made to the London Stock Exchange for the
new Ordinary Shares to be admitted to trading on AIM. It is
expected that admission of the 400,000 new Ordinary Shares to
trading on AIM will become effective on, or around, 6 October 2020
("Admission").
Total voting rights
Following Admission, the Company will have 454,993,227 Ordinary
Shares in issue with each share carrying the right to one vote. The
Company has no Ordinary Shares held in treasury. The total number
of voting rights in the Company following Admission will therefore
be 454,993,227.
Enquiries:
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Christopher Mills, Non-Executive Chairman Tel: 029 2071 0570
Julian Baines, CEO
Richard Evans, FD & COO
N+1 Singer (Nomad & Broker) Tel: 020 7496 3000
Aubrey Powell / George Tzimas / Carlo Spingardi
(Corporate Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: 020 7933 8780 or ekf@walbrookpr.com
Paul McManus/ Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading point-of-care diagnostics and central
laboratory assay manufacturer with an estimated 80,000 hemoglobin,
hematocrit, HbA1c, glucose and lactate analyzers in regular use
across more than 100 countries. EKF specializes in developing tests
for use in anemia and diabetes diagnosis and management, as well as
providing a portfolio of reagents for use in clinical chemistry
analyzers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSDWFUSESSEDU
(END) Dow Jones Newswires
October 01, 2020 02:00 ET (06:00 GMT)
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Apr 2023 to Apr 2024